NCT05893693View on ClinicalTrials.gov

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Relapsed and/or Refractory Multiple MyelomaPlasma Cell Leukemia in Relapse
Interventions
OTHER

Biological

CT0594CP

Trial Locations (1)

200333

RECRUITING

Shanghai Tongji Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Aibin Liang，MD，Ph.D.

OTHER